Kindred Biosciences upgraded to Outperform from Market Perform at BMO Capital BMO Capital upgraded Kindred based on increased expectations for the AtoKin product which recently entered Phase 3. The firm now believes AtoKin will be mover competitive with Apoquel and that it can reach $95M-$100M peak sales by 2020-2023. Price target raised to $30 from $15.
News For KIN From The Last 14 Days
Check below for free stories on KIN the last two weeks.